OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT) Files An 8-K Entry into a Material Definitive Agreement

OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01Entry into a Material Definitive Agreement.

Story continues below

On December 21, 2018, Opiant Pharmaceuticals, Inc. (the “Company”) entered into an exclusive global licensing agreement (“License”) with Sanofi (NYSE:SNY), a French corporation (“Sanofi”), for the development and commercialization of Sanofi’s compound AVE1625 (drinabant) for the treatment of acute cannabinoid overdose (“ACO”). ACO is most often linked to the ingestion of “edibles” containing large quantities of tetrahydrocannabinol (“THC”) and synthetic cannabinoids that are more potent and less expensive than marijuana. Edibles, sold as brownies, cookies and candies, pose particular risks for children, who often consume these by accident. The Company intends to develop drinabant, a cannabinoid CB-1 receptor antagonist, as an injectable for administration in an emergency department setting.

Under the terms of the License, the Company will pay Sanofi an upfront fee of $500,000, with any further payments contingent upon the Company achieving certain clinical, regulatory and sales milestones. The Company will assume all development and commercial responsibilities related to drinabant.

A copy of the License is attached to this Current Report on Form 8-K and is incorporated herein by reference. The description of the License provided herein is qualified in its entirety by reference to the terms of the License as set forth in Exhibit 10.1.

On December 26, 2018, the Company issued a press release announcing the entry into the License. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.Description

** Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.

OPIANT PHARMACEUTICALS, INC. Exhibit
EX-10.1 2 opiant_sanofixave1625licen.htm EXHIBIT 10.1 Exhibit Exhibit 10.1CONFIDENTIAL TREATMENT REQUESTEDCONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSIONLICENSE AGREEMENTbetweenSANOFIandOPIANT PHARMACEUTICALS,…
To view the full exhibit click here

About OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT)

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

An ad to help with our costs